Recently Featured

Alnylam Scolded Over Promotional Activity After Pfizer Complaint

June 27, 2026
Alnylam Pharmaceuticals has faced scrutiny from the Prescription Medicines Code of Practice Authority (PMCPA) following a complaint lodged by Pfizer regarding its promotional activities at a recent cardiology congress. The PMCPA’s initial ruling criticized Alnylam for breaching marketing regulations, reflecting the increasing vigilance of regulatory bodies in the pharmaceutical sector regarding promotional conduct. However, in…

AI Enhances Long-Term Partnerships in Women’s Health Brands

June 27, 2026
Recent advancements in artificial intelligence (AI) are poised to transform how women’s health brands engage with their audiences, fostering deeper, more enduring partnerships. Women’s health audiences have long memories and finely tuned instincts for what is performative, making it essential for brands to move beyond episodic interactions and cultivate genuine relationships. As AI technology enables…

The first 14 days: How specialty programs set patients up for success

June 27, 2026
As specialty medicines play a growing role in healthcare, the patient journey that follows is equally critical. The first 14 days after a patient starts a specialty medication can significantly influence adherence and overall treatment outcomes. This initial period is crucial for establishing a strong foundation for patient success, as it often determines whether patients…

Intellia Therapeutics Shares Surge Following Positive Phase III Data

June 26, 2026
A second positive Phase III data readout in two months has propelled Intellia Therapeutics (Nasdaq: NTLA) shares up over 76% in the past six months, including a notable 29% increase this past week. This surge follows the successful meeting of three key secondary endpoints by the company’s lead pipeline candidate, lonvoguran ziclumeran (lonvo-z), in a…

Ongoing Cases